15/06/2026
In pharmaceuticals, trust is not a marketing concept; it is operational. It is integral to business activity and service delivery. It sits within quality systems, regulatory filings, supplier audits, and the expectation that every product reaching a patient has been produced responsibly.
For STADA, sustainability follows the same logic. It is not positioned as a separate corporate initiative running alongside the business; it is being built directly into the mechanics of procurement, governance and executive oversight, so that transparency becomes structural rather than reactive.
With more than 25,000 SKUs spanning generics, consumer healthcare and specialty pharmaceuticals, STADA operates one of the broadest portfolios in European healthcare. Approximately 50 percent of its products are manufactured externally through more than 400 contract manufacturing organisations and several hundred raw material and packaging suppliers. That scale creates reach and significant responsibilty.
Read the full article to explore how trust, transparency and sustainability are being embedded into pharmaceutical operations at scale via the link in our bio.
Or listen to the interview with Martin Hess, Head of Global Sustainability at STADA, on The Business Enquirer Podcast, available on Spotify.